{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:25:50Z","timestamp":1764332750799,"version":"build-2065373602"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Antibody-mediated rejection (AMR) is a major cause of kidney allograft failure. Its molecular mechanisms are multifaceted and may include a role of complement activation via the classical pathway. Here, we investigated whether noninvasive complement monitoring adds predictive power to the diagnosis of AMR in the setting of donor-specific antibody (DSA) positivity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>In this cross-sectional study, 741 kidney transplant recipients with stable graft function \u2265180 days posttransplantation were screened for the presence of human leukocyte antigen (HLA) alloantibodies. Eighty-three of 111 DSA-positive recipients underwent protocol biopsies and were tested for blood and urinary levels of complement proteins (C1q, C4, C3) and activation products (C4d, C3a, C5a, C5b-9).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Forty-seven recipients were diagnosed with AMR, and 21 were C4d-positive. While biopsy-confirmed AMR (and C4d) associated with DSA-binding strength (IgG mean fluorescence intensity of the immunodominant DSA versus AMR; area under the receiver operating characteristic curve: 0.76), tested complement markers did not have any predictive value for rejection (area under the receiver operating characteristic curve: 0.49\u20130.56). There were, however, tight correlations between complement activation products in urine and protein\/creatinine ratio (<jats:italic toggle=\"yes\">\u03c1<\/jats:italic> = 0.44\u20130.64; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Analysis of death-censored graft survival over a median of 60 months revealed no independent associations with levels of complement markers in blood or urine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Complement patterns in blood and urine failed to identify AMR in late biopsies and may have no relevant diagnostic value in this particular context.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000000915","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T13:55:14Z","timestamp":1561730114000},"page":"e470","source":"Crossref","is-referenced-by-count":7,"title":["Complement Markers in Blood and Urine: No Diagnostic Value in Late Silent Antibody-Mediated Rejection"],"prefix":"10.1097","volume":"5","author":[{"given":"Blanka","family":"Mez\u0151","sequence":"first","affiliation":[{"name":"IIIrd Department of Internal Medicine and MTA-SE Research Group of Immunology and Hematology, Research Laboratory, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Heilos","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg A.","family":"B\u00f6hmig","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farsad","family":"Eskandary","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Wahrmann","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Bond","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Kozakowski","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Medical University of Vienna, Vienna, Austria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip F.","family":"Halloran","sequence":"additional","affiliation":[{"name":"Alberta Transplant Applied Genomics Centre, ATAGC, University of Alberta, Edmonton, AB, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisztina","family":"Rusai","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Proh\u00e1szka","sequence":"additional","affiliation":[{"name":"IIIrd Department of Internal Medicine and MTA-SE Research Group of Immunology and Hematology, Research Laboratory, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,7]]},"reference":[{"key":"R1-20231002","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJMra1802677","article-title":"Antibody-mediated rejection of solid-organ allografts.","volume":"379","author":"Loupy","year":"2018","journal-title":"N Engl J Med"},{"key":"R2-20231002","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transplant"},{"key":"R3-20231002","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nrneph.2016.85","article-title":"Molecular assessment of disease states in kidney transplant biopsy samples.","volume":"12","author":"Halloran","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"R4-20231002","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection.","volume":"29:","author":"Eskandary","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"R5-20231002","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/ajt.14520","article-title":"Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: a multicenter, prospective, randomized, double-blind clinical trial.","volume":"18","author":"Moreso","year":"2018","journal-title":"Am J Transplant"},{"key":"R6-20231002","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1681\/ASN.2017121296","article-title":"Any progress in the treatment of antibody-mediated rejection?","volume":"29","author":"Budde","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"R7-20231002","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1111\/j.1600-6143.2008.02428.x","article-title":"Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes.","volume":"8","author":"Bartel","year":"2008","journal-title":"Am J Transplant"},{"key":"R8-20231002","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/ajt.13347","article-title":"Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody.","volume":"15","author":"Wiebe","year":"2015","journal-title":"Am J Transplant"},{"key":"R9-20231002","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/TP.0000000000001195","article-title":"Diagnostic contribution of donor-specific antibody characteristics to uncover late silent antibody-mediated rejection-results of a cross-sectional screening study.","volume":"101","author":"Eskandary","year":"2017","journal-title":"Transplantation"},{"key":"R10-20231002","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nrneph.2012.212","article-title":"The role of complement in antibody-mediated rejection in kidney transplantation.","volume":"8","author":"Stegall","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"R11-20231002","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41581-018-0071-x","article-title":"The multifaceted role of complement in kidney transplantation.","volume":"14","author":"Biglarnia","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"R12-20231002","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.molmed.2015.02.004","article-title":"The perfect storm: HLA antibodies, complement, fc\u03b3rs, and endothelium in transplant rejection.","volume":"21","author":"Thomas","year":"2015","journal-title":"Trends Mol Med"},{"key":"R13-20231002","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/ki.1993.187","article-title":"Capillary deposition of C4D complement fragment and early renal graft loss.","volume":"43","author":"Feucht","year":"1993","journal-title":"Kidney Int"},{"key":"R14-20231002","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2215\/CJN.09901014","article-title":"Capillary C4D and kidney allograft outcome in relation to morphologic lesions suggestive of antibody-mediated rejection.","volume":"10","author":"Kiki\u0107","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"R15-20231002","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1302506","article-title":"Complement-binding anti-HLA antibodies and kidney-allograft survival.","volume":"369","author":"Loupy","year":"2013","journal-title":"N Engl J Med"},{"key":"R16-20231002","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/00007890-199410270-00008","article-title":"Assessment of soluble adhesion molecules (sicam-1, svcam-1, selam-1) and complement cleavage products (sc4d, sc5b-9) in urine. Clinical monitoring of renal allograft recipients.","volume":"58","author":"Bechtel","year":"1994","journal-title":"Transplantation"},{"key":"R17-20231002","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/TP.0b013e3181641d8c","article-title":"Urinary C4D does not correlate with C4d-staining in peritubular capillaries but reflects nonspecific glomerular injury.","volume":"85","author":"H\u00f6nger","year":"2008","journal-title":"Transplantation"},{"key":"R18-20231002","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1745-6215-15-107","article-title":"Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT study): study protocol for a randomized controlled trial.","volume":"15","author":"Eskandary","year":"2014","journal-title":"Trials"},{"key":"R19-20231002","doi-asserted-by":"crossref","first-page":"929","DOI":"10.7326\/0003-4819-141-12-200412210-00009","article-title":"Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease.","volume":"141","author":"Rule","year":"2004","journal-title":"Ann Intern Med"},{"key":"R20-20231002","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ajt.12590","article-title":"Banff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions.","volume":"14","author":"Haas","year":"2014","journal-title":"Am J Transplant"},{"key":"R21-20231002","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1111\/ajt.14329","article-title":"Real time central assessment of kidney transplant indication biopsies by microarrays: the INTERCOMEX study.","volume":"17","author":"Halloran","year":"2017","journal-title":"Am J Transplant"},{"key":"R22-20231002","doi-asserted-by":"crossref","first-page":"e94197","DOI":"10.1172\/jci.insight.94197","article-title":"Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes.","volume":"2","author":"Reeve","year":"2017","journal-title":"JCI Insight"},{"key":"R23-20231002","first-page":"205","article-title":"A micromodification of the CH50 test for the classical pathway of complement.","volume":"14","author":"Fetterhoff","year":"1984","journal-title":"J Clin Lab Immunol"},{"key":"R24-20231002","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0022-1759(88)90160-3","article-title":"An ELISA technique for the measurement of C1Q in cerebrospinal fluid.","volume":"114","author":"Delamarche","year":"1988","journal-title":"J Immunol Methods"},{"key":"R25-20231002","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1538-7836.2012.04674.x","article-title":"Complement activation in thrombotic thrombocytopenic purpura.","volume":"10","author":"R\u00e9ti","year":"2012","journal-title":"J Thromb Haemost"},{"key":"R26-20231002","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1681\/ASN.V114700","article-title":"Complement activation products in the urine from proteinuric patients.","volume":"11","author":"Morita","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R27-20231002","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/ndt\/gfw027","article-title":"Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.","volume":"31","author":"Schwaiger","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"R28-20231002","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/ki.2014.166","article-title":"A systematic review of the role of C4D in the diagnosis of acute antibody-mediated rejection.","volume":"87","author":"Sapir-Pichhadze","year":"2015","journal-title":"Kidney Int"},{"key":"R29-20231002","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2215\/CJN.06230614","article-title":"Molecules great and small: the complement system.","volume":"10","author":"Mathern","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"R30-20231002","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1681\/ASN.2013101144","article-title":"Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss.","volume":"26","author":"Sicard","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R31-20231002","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1681\/ASN.2017050589","article-title":"Complement-activating anti-HLA antibodies in kidney transplantation: allograft gene expression profiling and response to treatment.","volume":"29","author":"Lefaucheur","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"R32-20231002","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/ajt.13115","article-title":"The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors.","volume":"15","author":"Venner","year":"2015","journal-title":"Am J Transplant"},{"key":"R33-20231002","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MOT.0b013e32835d4daf","article-title":"Pathology of C4d-negative antibody-mediated rejection in renal allografts.","volume":"18","author":"Haas","year":"2013","journal-title":"Curr Opin Organ Transplant"},{"key":"R34-20231002","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1096\/fj.15-275594","article-title":"Ig-like transcript 4 as a cellular receptor for soluble complement fragment C4d.","volume":"30","author":"Hofer","year":"2016","journal-title":"Faseb J"},{"key":"R35-20231002","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1084\/jem.168.1.127","article-title":"Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.","volume":"168","author":"Bindon","year":"1988","journal-title":"J Exp Med"},{"key":"R36-20231002","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/TP.0000000000000699","article-title":"C1Q binding activity of de novo donor-specific HLA antibodies in renal transplant recipients with and without antibody-mediated rejection.","volume":"99","author":"Yell","year":"2015","journal-title":"Transplantation"},{"key":"R37-20231002","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3389\/fimmu.2018.02237","article-title":"Interpretation of serological complement biomarkers in disease.","volume":"9","author":"Ekdahl","year":"2018","journal-title":"Front Immunol"},{"key":"R38-20231002","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1681\/ASN.2016091034","article-title":"Cell-free DNA and active rejection in kidney allografts.","volume":"28","author":"Bloom","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R39-20231002","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1097\/TXD.0000000000000821","article-title":"Donor-derived cell-free DNA identifies antibody-mediated rejection in donor specific antibody positive kidney transplant recipients.","volume":"4","author":"Jordan","year":"2018","journal-title":"Transplant Direct"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01845228-201907000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T07:23:10Z","timestamp":1696231390000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01845228-201907000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,27]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000000915","relation":{},"ISSN":["2373-8731"],"issn-type":[{"type":"electronic","value":"2373-8731"}],"subject":[],"published":{"date-parts":[[2019,6,27]]}}}